- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Tesh Khullar Outlines Efforts Needed to Make Sure Providers Are Comfortable Prescribing Biosimilars
Tesh Khullar, senior vice president & advisor, Flatiron Health, explains what efforts are needed to make sure providers are comfortable prescribing biosimilars.
Tesh Khullar, senior vice president & advisor, Flatiron Health, explains what efforts are needed to make sure providers are comfortable prescribing biosimilars.
Transcript
What efforts are needed to providers are comfortable with prescribing biosimilars?
I think education around what biosimilars actually are and so, the physicians I talk to give me a great analogy that they’re using biosimilars right now because of the way monoclonal antibodies are made, one batch of Rituxan is different right now than a batch of Rituxan made 2 years ago. So essentially, you’re using a biosimilar right now, and as long as there’s a cost incentive to use cheaper therapies, I think the consumers are going to look at it just like they look at generics. That’s what I believe is going to happen.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
HMO and EPO Insurance Plans More Likely to Promote Use of Biosimilars
November 21st 2023Health plan type highly influences the likelihood of biosimilar uptake, with low-flexibility insurance plans more likely to have patients who either switched to a biosimilar or were initiated on a biosimilar.
Read More
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
November 20th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Read More
